Abstract
The vascular endothelium comprises a continuous single cell layer of endothelial cells which line the entire cardiovascular system. Impaired endothelial function underlies the pathogenesis and contributes to the progression of atherosclerosis. Oxidative stress, vasoconstriction, inflammation, proliferation and thrombosis occur in dysfunctional endothelium while the latter, is primarily mediated by platelet activation and adherence to vascular wall. Despite the primary action of antiplatelet agents including aspirin, P2Y12 ADP receptor antagonists and glycoprotein IIb/IIIa inhibitors, a growing body of literature suggests that an important mechanism of their action involves complex modulation of endothelial function via platelet-endothelial interactions, modification of the inflammatory cytokine cascade and nitric oxide mediated effects. These agents represent the mainstay in pharmacological treatment of all aspects of cardiovascular disease both in primary and secondary prevention. However beyond these properties, it is important to note that pharmacological modification of endothelial dysfunction has been postulated as a therapeutic target for reduction of cardiovascular events.
Keywords: Endothelial function, antiplatelets, cardiovascular disease, oxidative stress, inflammation.
Current Pharmaceutical Design
Title:The Impact of Antiplatelet Treatment on Endothelial Function
Volume: 22 Issue: 29
Author(s): Emmanuel Androulakis, Karl Norrington, Constantinos Bakogiannis, Eirini Lioudaki, Gerasimos Siasos and Dimitris Tousoulis
Affiliation:
Keywords: Endothelial function, antiplatelets, cardiovascular disease, oxidative stress, inflammation.
Abstract: The vascular endothelium comprises a continuous single cell layer of endothelial cells which line the entire cardiovascular system. Impaired endothelial function underlies the pathogenesis and contributes to the progression of atherosclerosis. Oxidative stress, vasoconstriction, inflammation, proliferation and thrombosis occur in dysfunctional endothelium while the latter, is primarily mediated by platelet activation and adherence to vascular wall. Despite the primary action of antiplatelet agents including aspirin, P2Y12 ADP receptor antagonists and glycoprotein IIb/IIIa inhibitors, a growing body of literature suggests that an important mechanism of their action involves complex modulation of endothelial function via platelet-endothelial interactions, modification of the inflammatory cytokine cascade and nitric oxide mediated effects. These agents represent the mainstay in pharmacological treatment of all aspects of cardiovascular disease both in primary and secondary prevention. However beyond these properties, it is important to note that pharmacological modification of endothelial dysfunction has been postulated as a therapeutic target for reduction of cardiovascular events.
Export Options
About this article
Cite this article as:
Androulakis Emmanuel, Norrington Karl, Bakogiannis Constantinos, Lioudaki Eirini, Siasos Gerasimos and Tousoulis Dimitris, The Impact of Antiplatelet Treatment on Endothelial Function, Current Pharmaceutical Design 2016; 22 (29) . https://dx.doi.org/10.2174/1381612822666160603020003
DOI https://dx.doi.org/10.2174/1381612822666160603020003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endoplasmic Reticulum and Mitochondria: Independent Roles and Crosstalk in Fatty Liver Diseases and Hepatic Inflammation
Current Pharmaceutical Design Redox-Sensitive Smart Nanosystems for Drug and Gene Delivery
Current Organic Chemistry Inflammatory Aspects of Depression
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Recognition and Drug-Lead Identification: What Can Molecular Simulations Tell Us?
Current Medicinal Chemistry Cannabinoid Receptors as Therapeutic Targets
Current Pharmaceutical Design Optogenetics of the Spinal Cord: Use of Channelrhodopsin Proteins for Interrogation of Spinal Cord Circuits
Current Protein & Peptide Science Gastric Cytoprotection Beyond Prostaglandins: Cellular and Molecular Mechanisms of Gastroprotective and Ulcer Healing Actions of Antacids
Current Pharmaceutical Design Improvement of Adoptive Cellular Immunotherapy of Human Cancer Using Ex-Vivo Gene Transfer
Current Gene Therapy Acute Hepatitis C: Clinical Aspects, Diagnosis, and Outcome of Acute HCV Infection
Current Pharmaceutical Design Safflor Protected Rat Cerebral Ischemia-Reperfusion Injury Through Inhibiting the Expression of NF-kB and IL-1β
Neuroscience and Biomedical Engineering (Discontinued) Cell Death: Tipping the Balance of Autoimmunity and Tissue Repair
Current Pharmaceutical Design Associations of Body Mass Index and Obesity-Related Genetic Variants with Serum Metabolites
Current Metabolomics Omega-3 Polyunsaturated Fatty Acid Derived Lipid Mediators and their Application in Drug Discovery
Current Medicinal Chemistry Creating Chemical Diversity to Target Protein Kinases
Combinatorial Chemistry & High Throughput Screening The Anti-Inflammatory Role of Minocycline in Alzheimer´s Disease
Current Alzheimer Research Redox Homeostasis, Bioactive Agents and Transduction Therapy
Current Signal Transduction Therapy Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance
Current Topics in Medicinal Chemistry Novel Insights into V-ATPase Functioning: Distinct Roles for its Accessory Subunits ATP6AP1/Ac45 and ATP6AP2/(pro) Renin Receptor
Current Protein & Peptide Science Modulatory Factors Responsible for Neoangiogenesis in Young Patients with Long-Standing Diabetes Mellitus Type 1
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) New Immunosuppressants in Clinical Trial
Current Drug Targets - Cardiovascular & Hematological Disorders